Key Highlights
- First-ever computational histology AI (CHAI) assay with predictive biomarkers validated across 1000+ patients.
- Proven to identify high-risk patients where BCG therapy may be ineffective.
- Presented at the 2024 Annual Meeting of the American Urological Association.
Source: Business Wire
Notable Quotes
- “Our study demonstrates that the CHAI biomarkers can identify patients with high-risk non-muscle invasive bladder cancer for whom BCG therapy is likely to be ineffective,” – Yair Lotan, M.D., Professor of Urology, Chief of Urologic Oncology at UT Southwestern Medical Center
- “With response rates to BCG treatment as low as 50%, physicians have long sought tools like our CHAI biomarkers to better manage patient care,” – Anirudh Joshi, co-founder and CEO at Valar Labs
- “We are incredibly excited to have completed the validation of these biomarkers for predicting response to the standard of care therapy in high-risk non muscle-invasive bladder cancer,” – Damir Vrabac, co-founder and COO at Valar Labs
SoHC's Take
Valar Labs’ introduction of the CHAI assay marks a significant milestone in bladder cancer treatment, providing a robust tool for physicians to make more informed treatment decisions. This innovation not only addresses a critical gap in predictive diagnostics but also stands to revolutionize the management of bladder cancer, offering new hope to thousands affected by this challenging disease. With the largest validation study of its kind, Valar Labs is at the forefront of enhancing patient outcomes through precision medicine.
